EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance

Breast Cancer Research and Treatment

Volumn 122, Issue 3, 2010, Pages 685-697

  Dua, Rajiv ^a   Zhang, Jianhuan ^a   Nhonthachit, Phets ^a,b   Penuel, Elicia ^a   Petropoulos, Chris ^a   Parry, Gordon ^a  

^a Genentech   (United States)

^b ROSS UNIVERSITY SCHOOL OF MEDICINE   (Dominica)

Author keywords

Breast cancer; EGFR; HER2; Trastuzumab resistance; Veratag

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ESTROGEN RECEPTOR; LAPATINIB; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA; TRASTUZUMAB; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; MONOCLONAL ANTIBODY;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CELL PROLIFERATION; CELL SURFACE; CELL VIABILITY; CONTROLLED STUDY; DIMERIZATION; DOWN REGULATION; DRUG ACTIVITY; DRUG SENSITIVITY; FLOW CYTOMETRY; GENE ACTIVATION; GENE INACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SURVIVAL TIME; UPREGULATION; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; ANTIBODIES, MONOCLONAL, HUMANIZED;

EID: 77955559443     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0592-x     Document Type: Article

References (31)

1. HS Cho K Masonn KX Ramyar, et al. 2003 Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab Nature 421 756 760 10.1038/nature01392 1:CAS:528:DC%2BD3sXhsV2rtrw%3D 12610629 (Pubitemid 36227628)
2. Y Yarden MX Sliwkowski 2001 Untangling the ERBB signalling network Nat Mol Cell Biol 2 127 137 10.1038/35052073 1:CAS:528:DC%2BD3MXivVWnt7k%3D (Pubitemid 33674041)
3. DJ Slamon GM Clark SG Wong, et al. 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 177 182 10.1126/science.3798106 1:CAS:528:DyaL2sXhtVSht7s%3D 3798106
4. DJ Slamon B Leyland-Jones S Shak, et al. 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2 N Engl J Med 344 783 792 10.1056/NEJM200103153441101 1:CAS:528: DC%2BD3MXisVGktrc%3D 11248153 (Pubitemid 32222155)
5. EH Romond EA Perez J Bryant, et al. 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673 1684 10.1056/NEJMoa052122 1:CAS:528:DC%2BD2MXhtFansr3F 16236738 (Pubitemid 41464706)
6. Y Nagata KH Lan X Zhou, et al. 2004 PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients Cancer Cell 6 117 127 10.1016/j.ccr.2004.06.022 1:CAS:528: DC%2BD2cXns1arsr8%3D 15324695 (Pubitemid 39485684)
7. Ginestier C, Adelaide J, Gonclaves A, et al (2007) ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines. Oncogene 26:7163-7169
8. DL Shattuck JK Miller KL Carraway, et al. 2008 Met receptor contributes to trastuzumab resistance of Her-2 overexpressing breast cancer cells Cancer Res 68 1471 1477 10.1158/0008-5472.CAN-07-5962 1:CAS:528:DC%2BD1cXislagu70%3D 18316611 (Pubitemid 351346855)
9. R Nahta LX Yuan B Zhang, et al. 2005 Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells Cancer Res 65 1118 1128 10.1158/0008-5472.CAN-04-3841 (Pubitemid 41713383)
10. Y Lu X Zi Y Zhao, et al. 2001 Insulin-like growth factor-I receptor signaling and resistance to Trastuzuman (Herceptin) J Natl Cancer Inst 93 1852 1857 10.1093/jnci/93.24.1852 1:CAS:528:DC%2BD38XltVWluw%3D%3D 11752009
11. CA Ritter PT Marianela C Rinehart, et al. 2007 Human breast cancer cells selected for resistance in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network Clin Cancer Res 13 4909 4919 10.1158/1078-0432.CCR-07-0701 1:CAS:528:DC%2BD2sXptVGmtLg%3D 17699871 (Pubitemid 47294799)
12. A Prat J Baselga 2008 The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2 Nat Clin Pract Oncol 5 531 542 10.1038/ncponc1179 1:CAS:528:DC%2BD1cXhtVGgt7fE 18607391
13. RD Mass C Vogel M Murphy, et al. 2001 Relationship of estrogen receptor (ER) status to clinical benefit in clinical trials of Herceptin Eur J Cancer 37 suppl 6 S190 10.1016/S0959-8049(01)81186-2
14. A Brufsky B Lembersky K Schiffman, et al. 2005 Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer Clin Breast Cancer 6 247 252 10.3816/CBC.2005.n.027 16137436
15. G Sabnis A Schayowitz O Goloubeva, et al. 2009 Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen Cancer Res 69 1416 1428 10.1158/0008-5472.CAN-08-0857 1:CAS:528:DC%2BD1MXhslyns7s%3D 19190349
16. Y Shi W Huang Y Tan, et al. 2009 A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue Diagn Mol Pathol 18 11 21 10.1097/PDM.0b013e31818cbdb2 19214113
17. C Desmedt J Sperinde F Piette, et al. 2009 Quantitation of HER2 expression or HER2: HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH Diagn Mol Pathol 18 22 29 10.1097/PDM.0b013e31818ebc69 1:CAS:528:DC%2BD1MXit1eqsb8%3D 19214112
18. JM Stommel AC Kimmelman H Ying, et al. 2007 Coactivation of receptor tyrosine kinase affects the response of tumor cells to targeted therapies Science 318 287 290 10.1126/science.1142946 1:CAS:528:DC%2BD2sXhtFCjt7vP 17872411 (Pubitemid 47574858)
19. MD Pegram A Lipton DF Hayes, et al. 1998 Phase II recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment J Clin Oncol 22 2659 2671
20. CE Geyer J Forster D Lindquist, et al. 2006 Lapatinib plus capecitabine for HER-2 positive advanced breast cancer N Engl J Med 355 2733 2743 10.1056/NEJMoa064320 1:CAS:528:DC%2BD2sXhslSqsA%3D%3D 17192538 (Pubitemid 46021510)
21. FA Shepard JR Periera T Ciuleanu, et al. 2005 Erlotinib in previously treated non-small-lung cancer N Engl J Med 353 123 132 10.1056/NEJMoa050753 (Pubitemid 41058344)
22. MJ Moore D Goldstein J Hamm, et al. 2007 Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada clinical trials group J Clin Oncol 25 1960 1966 10.1200/JCO.2006.07.9525 1:CAS:528: DC%2BD2sXmvVWmsr0%3D 17452677 (Pubitemid 46972777)
23. Juntilla TT, Akita RW, Parsons K, et al (2009) Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15:429-440
24. MX Sliwkowski JA Lofgren GD Lewis, et al. 1999 Nonclinical studies addressing the mechanism of action of trastuzumab (herceptin) Sem Oncol 26 60 70 1:CAS:528:DyaK1MXmt1SisbY%3D
25. R Kumar HM Shepard J Medelson 1991 Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells Mol Cell Biol 11 979 986 1:CAS:528: DyaK3MXhsl2ntLg%3D 1671297
26. R Tao I Maruyama 2009 All EGF (ErbB) receptors have preformed homo- and heterodimeric structures in living cells J Cell Biol 121 3207 3217
27. X Yu KD Sharma T Takahasi, et al. 2002 Ligand-independent dimer formation of epidermal growth factor receptor (EGFR) is a step separable from ligand-induced EGFR signaling Mol Cell Biol 13 2547 2557 10.1091/mbc.01-08-0411 1:CAS:528:DC%2BD38XlvVCrsr8%3D (Pubitemid 34831354)
28. M Narayan JA Wilken LN Harris, et al. 2009 Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells Cancer Res 69 2191 2194 10.1158/0008-5472.CAN-08-1056 1:CAS:528:DC%2BD1MXjtFyqt74%3D 19276389
29. D Zhang A Pal WG Bornmann, et al. 2008 Activity of lapatinib is independent of EGFR expression level in HER2-overexpressin breast cancer cells Mol Cancer Ther 7 1846 1850 10.1158/1535-7163.MCT-08-0168 1:CAS:528: DC%2BD1cXoslCgtLc%3D 18644997
30. BN Rexer R Ghosh CL Arteaga 2009 Inhibition of PI3K and MEK: it is all about combinations and biomarkers Clin Cancer Res 15 4518 4520 10.1158/1078-0432.CCR-09-0872 1:CAS:528:DC%2BD1MXosV2ltrc%3D 19584146
31. M Scaltriti C Verma M Guzman, et al. 2008 Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity Oncogene 28 803 814 10.1038/onc.2008.432 19060928